-$0.11 Earnings Per Share Expected for OpGen Inc (OPGN) This Quarter
Equities research analysts expect OpGen Inc (NASDAQ:OPGN) to report earnings of ($0.11) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for OpGen’s earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.14). OpGen posted earnings of ($0.23) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 52.2%. The firm is expected to issue its next quarterly earnings results on Monday, October 23rd.
According to Zacks, analysts expect that OpGen will report full year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.67) to ($0.42). For the next year, analysts forecast that the company will post earnings of ($0.31) per share, with EPS estimates ranging from ($0.45) to ($0.16). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for OpGen.
OPGN has been the topic of a number of recent research reports. HC Wainwright set a $1.00 price target on shares of OpGen and gave the stock a “buy” rating in a report on Tuesday, July 18th. Zacks Investment Research lowered shares of OpGen from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Dawson James reiterated a “buy” rating on shares of OpGen in a report on Monday, June 19th.
Shares of OpGen (NASDAQ:OPGN) traded down 2.062% during mid-day trading on Friday, hitting $0.285. 807,800 shares of the company’s stock traded hands. OpGen has a 52 week low of $0.27 and a 52 week high of $3.10. The firm has a 50-day moving average of $0.31 and a 200 day moving average of $0.71. The company’s market cap is $14.69 million.
WARNING: “-$0.11 Earnings Per Share Expected for OpGen Inc (OPGN) This Quarter” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/15/0-11-earnings-per-share-expected-for-opgen-inc-opgn-this-quarter.html.
In other news, Chairman Jven Capital, Llc bought 1,875,000 shares of the stock in a transaction that occurred on Tuesday, July 18th. The stock was acquired at an average price of $0.40 per share, with a total value of $750,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Timothy C. Dec bought 65,000 shares of the stock in a transaction that occurred on Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, with a total value of $26,000.00. Following the purchase, the chief financial officer now directly owns 118,966 shares of the company’s stock, valued at $47,586.40. The disclosure for this purchase can be found here. 53.27% of the stock is owned by company insiders.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. increased its position in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 at the end of the most recent reporting period. 8.13% of the stock is currently owned by institutional investors.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.